Elvira Moscarella1, Cristina Pellegrini2, Riccardo Pampena3, Giuseppe Argenziano1, Marco Manfredini4, Claudia Martorelli2, Alessia Ciarrocchi5, Emi Dika6, Ketty Peris7, Ambra Antonini2, Gianluca Cipolloni8, Roberto Alfano9, Caterina Longo3,4, Maria Concetta Fargnoli2. 1. Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy. 2. Department of Dermatology, University of L'Aquila, L'Aquila, Italy. 3. Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy. 4. Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy. 5. Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy. 6. Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy. 7. Institute of Dermatology, Catholic University, Rome, Italy. 8. Department of Pathology, San Salvatore Hospital, L'Aquila, Italy. 9. Department of Anesthesiology, Surgery and Emergency, Second University of Naples, Naples, Italy.
Abstract
BACKGROUND: The association of clinical and dermoscopic features with BRAF mutational status has been poorly analysed in multiple primary melanomas (MPM). OBJECTIVE: To investigate whether concordance of BRAF mutational status is associated with dermoscopic similarity in multiple melanomas of the same patient. METHODS: Dermoscopic images and corresponding tissue sections of 124 melanomas from 62 patients with MPM were selected at four Italian Dermatology Departments. Similarity of dermoscopic appearance between multiple melanomas was evaluated according to the presence of the same prevalent dermoscopic feature. The BRAFV600 mutational status was analysed with allele-specific TaqManTM assays or pyrosequencing. Spearman's correlation and univariate and multivariate regression analysis were used for statistical analysis. RESULTS: A similar dermoscopic appearance was identified in 38.7% (24/62) of patients with MPM and was correlated with older age at first diagnosis (rho: 0.26; P: 0.042) and occurrence on sun-damaged skin (rho: 0.27; P: 0.037). The BRAFV600 mutation was detected in 39.5% (49/124) of the tumors and a concordant BRAF mutational status between melanomas in 33/62 (53.2%) MPM patients. Dermoscopically similar melanomas showed 5.7-fold higher odds to be concordant for BRAF mutational status compared to dissimilar lesions (OR: 5.7; 95% CI 1.7-19.5; P: 0.005). CONCLUSION: Dermoscopic similarity of multiple melanomas represents an independent clinical predictor of a concordant BRAF mutational status in MPM patients.
BACKGROUND: The association of clinical and dermoscopic features with BRAF mutational status has been poorly analysed in multiple primary melanomas (MPM). OBJECTIVE: To investigate whether concordance of BRAF mutational status is associated with dermoscopic similarity in multiple melanomas of the same patient. METHODS: Dermoscopic images and corresponding tissue sections of 124 melanomas from 62 patients with MPM were selected at four Italian Dermatology Departments. Similarity of dermoscopic appearance between multiple melanomas was evaluated according to the presence of the same prevalent dermoscopic feature. The BRAFV600 mutational status was analysed with allele-specific TaqManTM assays or pyrosequencing. Spearman's correlation and univariate and multivariate regression analysis were used for statistical analysis. RESULTS: A similar dermoscopic appearance was identified in 38.7% (24/62) of patients with MPM and was correlated with older age at first diagnosis (rho: 0.26; P: 0.042) and occurrence on sun-damaged skin (rho: 0.27; P: 0.037). The BRAFV600 mutation was detected in 39.5% (49/124) of the tumors and a concordant BRAF mutational status between melanomas in 33/62 (53.2%) MPM patients. Dermoscopically similar melanomas showed 5.7-fold higher odds to be concordant for BRAF mutational status compared to dissimilar lesions (OR: 5.7; 95% CI 1.7-19.5; P: 0.005). CONCLUSION: Dermoscopic similarity of multiple melanomas represents an independent clinical predictor of a concordant BRAF mutational status in MPM patients.
Authors: Giovanni Ponti; Giovanni Pellacani; Aldo Tomasi; Roberta Depenni; Monia Maccaferri; Antonio Maiorana; Giulia Orsi; Francesca Giusti; Stefano Cascinu; Marco Manfredini Journal: Mol Clin Oncol Date: 2019-11-07
Authors: Daniel Coelho de Sá; Juliana Abreu Pinheiro; Emmanuel Pereira Benevides Magalhães; Maria Araci de Andrade Pontes Journal: An Bras Dermatol Date: 2022-07-07 Impact factor: 2.113